Aperio Group LLC raised its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 15.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 171,289 shares of the medical instruments supplier’s stock after buying an additional 22,801 shares during the period. Aperio Group LLC owned 0.08% of Becton, Dickinson and worth $33,420,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BDX. BlackRock Inc. increased its position in Becton, Dickinson and by 2,427.8% in the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock worth $3,034,470,000 after buying an additional 15,887,611 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Becton, Dickinson and by 5.3% in the first quarter. Vanguard Group Inc. now owns 15,902,168 shares of the medical instruments supplier’s stock valued at $2,917,094,000 after buying an additional 796,034 shares during the period. Point72 Asset Management L.P. purchased a new position in shares of Becton, Dickinson and during the first quarter valued at approximately $101,993,000. Waverton Investment Management Ltd purchased a new position in shares of Becton, Dickinson and during the second quarter valued at approximately $68,448,000. Finally, Cantillon Capital Management LLC increased its position in shares of Becton, Dickinson and by 30.3% in the first quarter. Cantillon Capital Management LLC now owns 1,344,427 shares of the medical instruments supplier’s stock valued at $246,622,000 after buying an additional 312,926 shares during the period. Institutional investors and hedge funds own 75.71% of the company’s stock.

Shares of Becton, Dickinson and Company (NYSE BDX) traded up 0.40% during trading on Monday, hitting $197.84. 957,775 shares of the company’s stock were exchanged. The stock’s 50-day moving average price is $197.67 and its 200-day moving average price is $186.53. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $206.63. The stock has a market cap of $42.20 billion, a PE ratio of 32.86 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating analysts’ consensus estimates of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The company had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.06 billion. During the same period last year, the company posted $2.35 EPS. The firm’s quarterly revenue was down 5.1% compared to the same quarter last year. On average, equities analysts expect that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be paid a $0.73 dividend. The ex-dividend date is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.48%. Becton, Dickinson and’s payout ratio is currently 83.43%.

TRADEMARK VIOLATION NOTICE: This article was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/08/07/becton-dickinson-and-company-nysebdx-stake-raised-by-aperio-group-llc-updated.html.

Several research analysts recently commented on BDX shares. Zacks Investment Research downgraded shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, May 4th. Evercore ISI upgraded shares of Becton, Dickinson and from an “in-line” rating to an “outperform” rating and raised their price target for the stock from $186.00 to $200.00 in a research report on Monday, April 24th. Raymond James Financial, Inc. upgraded shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and decreased their price target for the stock from $210.00 to $180.00 in a research report on Friday, June 30th. Royal Bank Of Canada restated a “hold” rating and issued a $177.00 price target on shares of Becton, Dickinson and in a research report on Thursday, April 13th. Finally, Bank of America Corporation restated a “buy” rating and issued a $225.00 price target (up from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. One analyst has rated the stock with a sell rating, five have given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $194.69.

In other news, VP Jeffrey S. Sherman sold 28,765 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $185.98, for a total value of $5,349,714.70. Following the sale, the vice president now directly owns 70,821 shares in the company, valued at approximately $13,171,289.58. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.